Merck opts in for Dragonfly’s TriNKET cancer immunotherapy program
Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.
Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.
Zimmer Biomet has signed a deal to buy A&E Medical, maker of open chest surgery tools, for $250 million in cash. Separately, the company launched a new charitable foundation, and started a partnership with the NAACP in support of its public health and justice efforts.
Bayer has created a cell and gene therapy platform to support its growing pipeline of advanced therapy medicinal products. The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.
Aging has implications for a wide range of diseases. Researchers have been looking for ways to halt the aging process for millennia, but such methods remain elusive. Scientists at Harvard Medical School have now offered a glimmer of hope that the aging clock in the eye could be reversed—at least in animals.
Bayer strengthened its ties with Scottish artificial intelligence developer Blackford Analysis to build a one-stop shop for applications in medical imaging.
A phase 3 trial of Agios Pharmaceuticals’ mitapivat in a form of anemia has met its primary endpoint. The success gives Agios some of the data it needs to file for approval of the drug in pyruvate kinase (PK) deficiency next year.
After a brief stint in the antidote business, Boston Scientific has moved to hive off the specialty pharmaceuticals division it picked up through last year’s $4.2 billion acquisition of British oncology devicemaker BTG.
Several diseases are marked by retinal degeneration that eventually leads to blindness, including age-related macular degeneration (AMD) and retinitis pigmentosa. Targeting these diseases with gene and cell therapies is a popular pursuit, though picking the right targets has proven challenging.
The U.K. National Health Service (NHS) is looking to get an early start on the international rollout of Grail’s multi-cancer blood test with a pilot program spanning 165,000 people.
U.K.-based alpha-synuclein biotech Wren Therapeutics will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.